Synergia Medical is a preclinical medical device company that has developed NAO.VNS, a non‑metal optoelectronic neurostimulator for vagus nerve stimulation to treat drug‑resistant epilepsy. The company is preparing for First‑In‑Human clinical trials planned for early 2024. It is ISO 13485 certified, operational since 2015, and based in Belgium with a staff of 27 focused on preclinical studies, R&D, quality, and regulatory affairs. Synergia holds a portfolio of nine patents in 15 families and is supported by Wallonia Region grants and the European Innovation Council (Accelerator financing). The team includes co‑founders Attila Borbath (CEO) and Pascal Doguet, and the company has both a business‑oriented Board of Directors and a Scientific Advisory Board of experts in neural stimulation and epilepsy. Financially, the company has previously raised funding and uses the recent proceeds to advance toward clinical milestones. Founded in 2013 by Pascal Doguet and Attila Borbath, Synergia Medical develops opto-electronics medical devices for neurostimulation. Its lead product, NAOS, is a small-form, MRI-safe, implanted neurostimulation device targeting drug-resistant epilepsy with additional therapeutic applications. The company is conducting advanced-stage testing of NAOS ahead of a CE mark filing expected in 2019. Synergia intends to use the funding to complete final testing prior to CE mark submission. The company is also preparing for regulatory approval efforts in the United States where neurostimulation use is increasing. The Series A financing strengthens its position to advance regulatory and commercialization milestones.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2023